Inhibition of anti-tumor immunity by melanoma cell-derived Activin-A depends on STING
Katarina Pinjusic, Giovanna Ambrosini, Joao Lourenco, Nadine Fournier, Christian Iseli, Nicolas Guex, Olga Egorova, Sina Nassiri, Daniel B. Constam · 2024
Read Inhibition of anti-tumor immunity by melanoma cell-derived Activin-A depends on STING by Katarina Pinjusic, Giovanna Ambrosini, Joao Lourenco, Nadine Fournier, Christian Iseli, Nicolas Guex, Olga Egorova, Sina Nassiri, Daniel B. Constam (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10830842.txt.
Description
Katarina Pinjusic and co-authors study how a melanoma signal shields tumors from immunity in this paper, published in 2023. A growth factor called Activin-A is overproduced in many cancers and links to weight loss and poor outlook. Melanoma cells release it and, through it, blunt the killer T cells that attack tumors, which helps resist immunotherapy.
Using mouse melanoma grafts and single-cell gene reading, the team found that the immune evasion came with a broad inflammatory signal across cell types. The extra tumor growth depended in part on a DNA-sensing pathway inside the melanoma cells acting in a harmful way. Blocking that pathway may counter the signal's tumor help, the authors suggest.
Catalog record
| CREATOR | Katarina Pinjusic, Giovanna Ambrosini, Joao Lourenco, Nadine Fournier, Christian Iseli, Nicolas Guex, Olga Egorova, Sina Nassiri, Daniel B. Constam |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 64 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |